Psychedelic stocks: focus on their cash
Investing Experts
Navigating Psychedelic Medicine's Regulatory Landscape
This chapter examines recent challenges and developments in the psychedelic medicine sector, specifically the complex FDA approval process for MDMA therapy. It discusses the impact of an advisory panel's recommendation against Lycos's therapy on the industry's outlook and sentiment towards psychedelic stocks. Despite setbacks, the speakers remain optimistic about the long-term potential for innovative treatments, while highlighting key companies and their competitive positions in ongoing clinical trials.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
